Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPAND: ALLO-647 for Lymphodepletion in LBCL
NCT05714345Phase 2Terminated
- Sponsor
- Allogene Therapeutics
- Start
- Nov 2023
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of allo-647 in leukemia and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Allogene Therapeutics. Primary endpoint: Progression-Free Survival at 60 months. Started Nov 2023; status: terminated.
02
Drugs
allo-647
03
Conditions
leukemiadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05714345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05714345.